KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.
-
Upload
kory-riley -
Category
Documents
-
view
216 -
download
0
Transcript of KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.
![Page 1: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/1.jpg)
KS-CGMH Guideline for Diabetes Mellitus
Department of Endocrinology & Metabolism
August 31 2003
![Page 2: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/2.jpg)
Criteria for the Diagnosis of DM• Symptoms of diabetes plus random blood glucose
concentration >200 mg/dL or• Fasting plasma glucose >126 mg /dL @,*
or• 2-hour plasma glucose >200 mg/dL during 75-g
oral glucose tolerance test*
Normal <110 mg/dL, IFG (impaired fasting glucose) 110-125 mg/dLSymptoms as polyuria, polydyspsia, polyphagia, body weight loss@Fasting as no caloric intake for at least 8h *The criteria should be confirmed by repeat testing in a different day
![Page 3: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/3.jpg)
Classification of DM• Type 1 DM (5-10%) : immune mediated, idiopathic• Type 2 DM (90-95%)• Other specific type of DM (1-2%) A. Genetic defects of ß-cell function B. Genetic defects in insulin action C. Diseases of the exocrine pancreas D. Endocrinopathies E. Drugs- or chemical-related F. Infections G. Uncommon forms of immune-mediated disorder H. Other genetic syndromes associated with diabetes• Gestational diabetes mellitus (3-5% of all pregnancy)
![Page 4: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/4.jpg)
C-peptide in DM
A good marker of ß-cell function because of its equimolar secretion with insulin
Fasting plasma C-peptide < 0.35 ng/dL indicating insulin-dependent diabetes
![Page 5: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/5.jpg)
Type 1 DM
![Page 6: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/6.jpg)
Type 2 DM
![Page 7: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/7.jpg)
![Page 8: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/8.jpg)
Management of DM• Diet: 30 Kcal/Kg /day (IBW) Overweight: 25Kcal/Kg/day Underweight: 31-32Kcal/Kg/day 長期臥床 : 25Kcal/Kg/day, 輕度工作 : 30Kcal/Kg/day, 中度工作 : 35Kcal/Kg/day, 重度工作 : 40Kcal/Kg/day [M: IBW= (BH-80)x0.7, F: IBW=(BH-70)x0.6] [Content: carbohydrate 55%, protein 15%, fat 30%]• Exercise: blood sugar >300 or <75 is not suitable
• Medicine: insulin, oral anti-diabetes agents
![Page 9: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/9.jpg)
Insulin Therapy
• 0.5–1.0 U/kg/day first• Indication -- Type 1 DM -- Type 2 DM with acute illness, operation, pregnancy, OHA failure, DKA, HHS -- Short-acting: Regular (Actrapid HM) -- Intermediate-acting: NPH (Monotard HM) -- Long-action: Ultralente (Ultratard HM) -- Combination: Mixtard (70/30)
![Page 10: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/10.jpg)
Time of Action
Preparation Onset Peak Effective Maximum
Duration Duration
Regular 0.5-1.0 2-3 3-4 4-6
NPH 2-4 6-10 10-16 14-18
Ultralente 6-10 10-16 18-20 20-24
Mixtard 0.5-1.0 dual 10-16 14-18
(h)
![Page 11: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/11.jpg)
Insulin Regimens
![Page 12: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/12.jpg)
Insulin Regimens
![Page 13: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/13.jpg)
How to Adjust The Dosage of Insulin Twice Daily
Insulin regimen Qid Bid• Total daily dosage, divided into 2:1, 2/3 dose in
the morning, 1/3 dose in the evening• The morning dose divided into 2/3 NPH+1/3 RI• The evening dose divided into 1/2 NPH+1/2 RI
![Page 14: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/14.jpg)
Oral Anti-diabetes Agents
Class• Sulfonylurea
• Meglitinide• Biguanide• α-glucosidase inhibitor• Thiazolidinedione
Available Agents• Gliclazide (Diamicron),
Glipizide (Glidiab), Chlopropamide (Diabinese)
Glimepiride (Amaryl)
• Repaglinide (NovoNorm)
• Metformin (Glucophage)
• Acarbose (Glucobay)
• Pioglitazone (Actos)
![Page 15: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/15.jpg)
![Page 16: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/16.jpg)
Sulfonylureas Meglitinides Biguanides α-glucosidase inhibitor
Thiazolidine-diones
Hypoglycemia + ± BW gain + ± +GI upset + +Lactic acidosis +Hepatotoxicity +Increased plasma
volume +
Contraindication Significant
liver/kidney
dysfunction
Significant
liver
dysfunction
Cr (M) >1.5,
(F) >1.4 m/dl
Acidosis
CHF
Hypoxia
Radiocontrast
Gastroparesis
IBD
Active liver
disease orGPT >2.5 UNL
CHF
relative Short & rapid
onset
relative
![Page 17: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/17.jpg)
![Page 18: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/18.jpg)
Acute Complications of DM
• Diabetic ketoacidosis (DKA)
• Hyperglycemic hyperosmolar state (HHS)
• Hypoglycemia
![Page 19: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/19.jpg)
DKA (Diabetic Ketoacidosis) & HHS (Hyperglycemic Hyperosmolar State)
• DKA resulted from insulin deficiency combined with counterregulatory hormone excess.
• HHS resulted from hyperglycemia-induced an osmotic diuresis that leads to profound intravascular volume depletion, and the insulin deficiency is only relative and less severe.
• The precipitating events are infection, infarction, stroke, drugs, inadequate insulin administration, compromises water intake...
![Page 20: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/20.jpg)
ADA Diagnostic Criteria of DKA & HHS
• DKA: blood glucose >250 mg/dl, arterial pH <7.3, bicarbonate <15 mEq/l, and moderate ketonuria or ketonemia.
• HHS: blood glucose >600 mg/dl, arterial pH >7.3, bicarbonate >15 mEq/l, mild ketonuria or ketonemia, and effective serum osmolality >320 mOsm/kg H2O.
![Page 21: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/21.jpg)
Diabetic Ketoacidosis (DKA)
• Symptoms • Signs – nausea/vomiting – tachycardia – thirst/polyuria – dry mucous and/or – abdominal pain skin turgor – altered mental status – dehydration – SOB – tachypnea/Kussmaul respirations/distress – abdomen tenderness – fever – lethargy/coma
![Page 22: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/22.jpg)
![Page 23: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/23.jpg)
Hyperglycemic Hyperosmolar State (HHS)
• Symptoms • Signs
– polyuria – tachycardia
– orthostatic hypotension – dry mucous or/
– altered mental status and skin tugor
– (less) abdomen pain, – hypotension
nausea/vomiting,SOB – lethargy/coma
![Page 24: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/24.jpg)
![Page 25: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/25.jpg)
Hypoglycemia
• Definition
Plasma glucose level < 40-50 mg/dL• Whipple’s triad
A. symptoms consistent with hypoglycemia
(neuroglycopenic/autonomic)
B. a low plasma glucose concentration
C. relief of symptoms after the plasma glucose
level is raised
![Page 26: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/26.jpg)
How to manage a patient with low blood sugar level
• Does it meet the Whipple’s triad?
• Identify the cause of low blood sugar at bedside
• Give appropriate treatment
• Do not hold next insulin injection unless clinically warranted.
![Page 27: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/27.jpg)
Hypoglycemia
• Management 1. Oral treatment with glucose-containing material* (15g) if the patient is able to eat 2. Intravenous glucose (20g) followed by a constant infusion of 5 or 10% dextrose if indicated 3. Intramuscular glucacon (0.5-1.0 mg) * 方糖 2 至 4 塊 , 含糖果汁 1/2 瓶 (120cc) 等
![Page 28: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/28.jpg)
Chronic Complications of DM• Microvascular 1. Retinopathy, macular edema, cataracts 2. Neuropathy (sensory, motor, autonomic) 3. Nephropathy• Macrovascular 1. Coronary artery disease 2. Peripheral vascular disease 3. Cerebrovascular disease• Others 1. GI dysfunction (gastroparesis, diarrhea) 2. GU dysfunction (uropathy, sexual dysfunction) 3. Dermatologic
![Page 29: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/29.jpg)
DM Retinopathy
• Background (simple, non-proliferative)
-- retinal vascular microaneurysms, blot
hemorrhage, cotton wool spots• Proliferative
-- neovasculization• Treatment
-- prevention (intensive sugar control), regular eye
exam, laser photocoagulation
![Page 30: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/30.jpg)
DM Neuropathy• The most common DM neuropathy is distal symmetric polyneuropathy• Autonomic: resting tachycardia, orthostatic hypotension, neurogenic bladder, anhydrosis, gastroparesis• Treatment -- less satisfactory, intensive glycemic control, NCV, avoidance neurotoxin, supplement with vitamins and anti-neuralgia/anti-depressant agent
![Page 31: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/31.jpg)
DM Nephropathy
![Page 32: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/32.jpg)
DM Nephropathy
• Effective
-- near normalization of glycemia
-- strict BP control (without proteinuria <130/80,
with proteinuria <120/80 )
-- ACEI, ARB (drug of choice)
-- restriction of protein intake: 0.8g/kg/d, 10% of
daily caloric intake
![Page 33: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/33.jpg)
Dyslipidemia on DM
• Goal on dyslipidemia LDL HDL TG DM with or <100 >45(M) <150 without CVD >55(F)
(mg/dL)
• Dietary changes, life-style modification, drugs
![Page 34: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/34.jpg)
Drugs Choice for Dyslipidemia
![Page 35: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/35.jpg)
DM Foot• Factors which reduce the resistance of the tissues
to trauma– Macrovascular disease– Microvascular disease– Autonomic neuropathy
• Factors which increase the likelihood of trauma
– Motor neuropathy
– Sensory neuropathy
– Limited joint mobility
– Other
![Page 36: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/36.jpg)
EVALUATION OF THE DIABETIC FOOT
![Page 37: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/37.jpg)
DM Foot
ADA recommendation:
(1) Off-loading
(2) Debridement
(3) Wound dressing
(4) Appropriate use of antibiotics
(5) Revascularization
(6) Limited amputation
![Page 38: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/38.jpg)
DM Foot• Wound culture: --wound swab, pus aspiration• Simple cellulitis --Streptococcus: ampicillin, PCN --Staphylococcus: oxacillin• Severe infection need debridement --cefazolin+clindamycin (+GM with toxic sign)• Change antibiotic according to culture results and
clinical features
![Page 39: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/39.jpg)
Malignant External Otitis (MEO)
• A progressive, invasive, or necrotizing cellulitis of the external auditory canal, with granulation tissue formation
• Pseudomonas aerugenosa in almost all cases• Severe otalgia, purulent discharge• Cranial nerves impairment (CN VII, IX, X, XI)• Menigitis may resulted by more extension.• Treatment: pipril+GM for 4 to 6 weeks
![Page 40: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/40.jpg)
Emphysematous Pyelonephritis (EP)
• Severe bacterial UTI may result in EP, which reveals the presence of gas within the renal parenchyma, and may enter the perinephric space.
• Typical urinary pathogens: E. coli, K. pneumoniae, P. mirabilis, and Enterobacter.
• Mortality rate: 10% to 40%
• Treatment: antibiotics
• Nephrectomy: severe obstruction, or failed to medical treatment
![Page 41: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/41.jpg)
Other Complicated Urinary Tract Infections
• Renal papillary necrosis
• Renal abscess
• Perirenal abscess
• Emphysematous cystitis
![Page 42: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/42.jpg)
Emphysematous Cholecystitis (EC)
• EC is a rare complication of acute cholecystitis in which air is found in the lumen and wall of gallbladder, with possible extension to the pericholecystic space.
• Perforation and gangrene are more common.• Typical pathogens: E. coli, Clostridium perfringens.• Higher mortality rate in patients younger than 60.• Treatment: antibiotics (for G(+) and G(-))• Expeditious cholecystectomy
![Page 43: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/43.jpg)
• Mucormycosis may present as a rhinocerebral, pulmonary, cutaneous, GI, or disseminated form of the disease.
• The typical patient presents with DKA.
• The most common pathogen: Rhizopus spp.
• S/S: nasal discharge, headache, facial pain, proptosis, visual loss, deterioration of neurologic function, lethargy, fatal pneumonia, or extensive thrombosis
• Treatment: surgical debridement combined with amphotericin B
Mucormycosis
![Page 44: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/44.jpg)
Liver Abscess • Liver abscess caused by K. pneumoniae is a new clinical
syndrome that has emerged as an important infectious complication in diabetic patients in Taiwan.
• Clinical manifestation -- chills and fever, anorexia, weight loss, nausea and vomiting, weakness and malaise, abdominal pain, but may be non-specific and less obvious -- hepatomegaly, RUQ tenderness, or jaundice • An elevated serum ALK-P is the single most reliable
abnormality for liver abscess, and other tests of liver function may be normal.
• Drainage and antibiotic therapy (GM 1.5 mg/kg + metronidazole 500 mg q 8h) are important dual treatments for liver abscess.
![Page 45: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/45.jpg)
Necrotizing Fascitis
• It is any necrotizing soft tissue infection that spreads along fascial planes, either with or without overlying cellulitis.
• Type 1: mixed flora infection Type 2: group A Streptococcus alone or with Staphylococcus infection• It occurs anywhere, especially the legs.• Edema, warmth, and tenderness initially; and bullae,
gangrene, and ulceration later• Repeated surgical exploration with debridement and
antibiotic treatment are necessary.
![Page 46: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/46.jpg)
How to Approach a Diabetic Patient with Infection
No matter of what kind of infection impressed
• Detailed history taking
• Complete physical examination
• focused examination, including RUQ tenderness, CV angle knocking pain, suprapubic tenderness, musculoskeletal tenderness, perineum, prostate tenderness
![Page 47: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/47.jpg)
Treatment Goals in Diabetic patients
• A HbA1c <7 %
• B BP <130/80 mmHg
• C LDL-Cholesterol <100 mg%
HDL (male) >40 mg%,
(female) >50 mg%
TG <150 mg%
![Page 48: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/48.jpg)
Long-Term Treatment of DM
• Self-monitoring of blood sugar (individual frequency)• HbA1C testing (2-4 times/year)• Patient education (annual)• Eye examination (annual)• Foot examination (daily by patient, annual by
physician)• Screening for nephropathy (annual)• Blood pressure measurement• Lipid profile (annual)
![Page 49: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/49.jpg)
Approach New Patient on Ward
• Duration, recent treatment, average blood sugar level, 3P symptoms
• Family history• Co-morbidity• Vital sign (BP, HR, posture BP), Body weight• Physical examination (cardiovascular, neurologic) • CXR, EKG, CBC & D/C, SMA-12, U/R, S/R
![Page 50: KS-CGMH Guideline for Diabetes Mellitus Department of Endocrinology & Metabolism August 31 2003.](https://reader035.fdocuments.net/reader035/viewer/2022062800/56649de95503460f94ae4d8c/html5/thumbnails/50.jpg)
Approach New Patient on Ward
• HbA1c, CCr, 24-h urine protein, HDL-electrophoresis
• Finger stick blood sugar monitoring • Consult dietitian• Eye-ground examination